Eyenovia, Inc. is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for presbyopia, myopia progression and mydriasis.
Company profile
Ticker
EYEN
Exchange
Website
CEO
Sean Ianchulev
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
EYEN stock data
Latest filings (excl ownership)
8-K
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of
28 Feb 23
8-K
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
15 Feb 23
8-K
Other Events
30 Jan 23
424B3
Prospectus supplement
23 Dec 22
EFFECT
Notice of effectiveness
23 Dec 22
CORRESP
Correspondence with SEC
21 Dec 22
UPLOAD
Letter from SEC
20 Dec 22
S-3
Shelf registration
16 Dec 22
8-K
Eyenovia Announces FDA Acceptance of New Drug Application for MydCombi™ for In-Office Pupil Dilation
13 Dec 22
8-K
Eyenovia Announces Promotion of Bren Kern to Chief Operating Officer and Corporate Vice President
8 Dec 22
Transcripts
EYEN
Earnings call transcript
2022 Q3
11 Nov 22
EYEN
Earnings call transcript
2022 Q2
11 Aug 22
EYEN
Earnings call transcript
2022 Q1
13 May 22
EYEN
Earnings call transcript
2021 Q4
29 Mar 22
EYEN
Earnings call transcript
2021 Q3
12 Nov 21
EYEN
Earnings call transcript
2021 Q2
12 Aug 21
EYEN
Earnings call transcript
2021 Q1
13 May 21
EYEN
Earnings call transcript
2020 Q4
26 Mar 21
EYEN
Earnings call transcript
2020 Q3
10 Nov 20
EYEN
Earnings call transcript
2020 Q2
12 Aug 20
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 25.27 mm | 25.27 mm | 25.27 mm | 25.27 mm | 25.27 mm | 25.27 mm |
| Cash burn (monthly) | 1.37 mm | (no burn) | 2.41 mm | 1.53 mm | 2.27 mm | 2.13 mm |
| Cash used (since last report) | 8.11 mm | n/a | 14.27 mm | 9.07 mm | 13.46 mm | 12.62 mm |
| Cash remaining | 17.16 mm | n/a | 11.00 mm | 16.21 mm | 11.82 mm | 12.65 mm |
| Runway (months of cash) | 12.5 | n/a | 4.6 | 10.6 | 5.2 | 5.9 |
Institutional ownership, Q4 2022
30.4% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 28 |
| Opened positions | 5 |
| Closed positions | 7 |
| Increased positions | 8 |
| Reduced positions | 8 |
| 13F shares | Current |
|---|---|
| Total value | 4.21 bn |
| Total shares | 5.71 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Yoshida Shuhei | 1.74 mm | $8.19 mm |
| Vanguard | 919.32 k | $1.50 bn |
| Ianchulev Tsontcho | 746.67 k | $2.49 mm |
| Lasry Marc | 547.81 k | $892.93 mm |
| AMP Ameriprise Financial | 336.43 k | $548.00 mm |
| Palisade Capital Management | 315.03 k | $513.50 mm |
| Renaissance Technologies | 288.50 k | $470.00 k |
| Geode Capital Management | 260.07 k | $423.00 k |
| Millennium Management | 90.57 k | $148.00 k |
| BLK Blackrock | 74.75 k | $121.84 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Jan 23 | John P Gandolfo | Stock Option Common Stock | Grant | Acquire A | No | No | 2.16 | 68,235 | 147.39 k | 68,235 |
| 3 Jan 23 | Bren Kern | Stock Option Common Stock | Grant | Acquire A | No | No | 1.715 | 120,000 | 205.80 k | 120,000 |
| 30 Dec 22 | Grant Stuart M. | Common stock, par value $0.0001 | Buy | Acquire P | No | No | 1.5 | 21,753 | 32.63 k | 5,106,751 |
| 30 Dec 22 | Rowe Michael M | Common Stock, par value $.0001 | Buy | Acquire P | No | No | 1.54 | 10,000 | 15.40 k | 15,500 |
News
Eyenovia Announces Development Collaboration Agreement With Formosa Pharmaceuticals; Agreement Seeks To Combine Eyenovia's Optejet Dispensing Technology With Formosa's Unique APNT Nanoparticle Formulation Platform
15 Feb 23
Taiwan-Based Formosa Pharmaceuticals Has Entered Into A Collaboration Agreement With Eyenovia For The Development Of Ophthalmic Therapeutics. Deal Terms Not Disclosed
15 Feb 23
Eyenovia's Optejet Shows Lower Proinflammatory Cytokines Levels, Chemokines Than Standard Drops
12 Jan 23
Eyenovia Announces Results From Research Study Of Optejet
12 Jan 23
12 Health Care Stocks Moving In Thursday's Pre-Market Session
12 Jan 23
Press releases
Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30
23 Mar 23
Eyenovia Announces Independent Director Stephen Benjamin to Step Down to Assume Role of Head of White House's Office of Public Engagement
28 Feb 23
Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals
15 Feb 23
Formosa Pharmaceuticals Announces Development Collaboration Agreement with Eyenovia
15 Feb 23
Eyenovia Showcases Microdose Array Print (MAP™) Technology at CES 2023 in Las Vegas
31 Jan 23